Equities

SAB Biotherapeutics Inc

SABS:NAQ

SAB Biotherapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.42
  • Today's Change0.23 / 7.21%
  • Shares traded21.64k
  • 1 Year change-64.75%
  • Beta0.6398
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments571533
Total Receivables, Net05.568.01
Total Inventory------
Prepaid expenses2.341.492.64
Other current assets, total--06.34
Total current assets592250
Property, plant & equipment, net252831
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets845181
LIABILITIES
Accounts payable0.953.684.46
Accrued expenses7.321013
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.180.911.96
Other current liabilities, total1.360.056.66
Total current liabilities111526
Total long term debt3.424.173.76
Total debt4.605.085.72
Deferred income tax------
Minority interest------
Other liabilities, total120.6812
Total liabilities272043
SHAREHOLDERS EQUITY
Common stock0.000.010.00
Additional paid-in capital1538468
Retained earnings (accumulated deficit)(90)(48)(29)
Treasury stock - common(5.52)(5.52)0
Unrealized gain (loss)------
Other equity, total0.03----
Total equity573139
Total liabilities & shareholders' equity845181
Total common shares outstanding9.235.044.35
Treasury shares - common primary issue0.050.050
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.